Indication :
- Treatment of patients with a new diagnosis of Philadelphia chromosome (bcr-bl) positive (Ph+) chronic myeloid leukemia (CML) and also for the treatment of patients with Ph + CML in the chronic phase after failure of alpha interferon therapy or accelerated phase or blast cell crisis.
- Treatment of adult patients and children over 1 year old who are newly diagnosed with acute lymphoblastic leukemia with positive Philadelphia chromosome (Ph + ALL) is integrated with chemotherapy.
- Single treatment in adult patients with relapsed or refractory Ph+ ALL
- Treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene rearrangements.
- Treatment of adult patients with systemic mastocytosis (SM) without c-Kit D816V mutation or unknown c-Kit mutation status.
- Treatment of adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL).
- Treatment of adult patients with unresectable, relapsed and/or metastatic dermatofibrosarcoma protuberan (DFSP).
The effectiveness of Imatinib is based on the overall hematological and cytogenetic response rate and progression-free survival in CML, on the hematological and cytogenetic response rate in Ph+ ALL, MDS/MPD, on the hematological response rate in SM, HES/CEL, and on the objective response rate in DFSP .
Improved survival has been seen only in the chronic phase of newly diagnosed CML.
Compositions :
Each film-coated tablet contain Imatinib mesylate 119.5 mg ~ Imatinib 100 mg
Storage Condition :
Store below 30°C, protect from light.
